Tempus AI, Inc. (NASDAQ:TEM) is one of the 8 Best Genomics Stocks to Buy According to Analysts.
On June 3, Tempus AI, Inc. (NASDAQ:TEM) reported that it launched an open-source digital pathology consortium, alongside Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center, aiming to build a scalable platform and viewer
Chief of Pathology at YNHH, Chen Liu, said the group will “collaborate with leading academic and industry partners to help build an open, scalable, and interoperable digital pathology ecosystem” and commented that the shared standards will speed usage and improve workflows. Days later, on June 11, Tempus AI, Inc. (NASDAQ:TEM) shifted focus to cardiology and reported that its AI-enabled ECG model, cleared in 2024, achieved successful multi-center validation across 4,017 patients, with results published in “Heart Rhythm.” The company said the model exceeded pre-specified performance thresholds in predicting one-year atrial fibrillation risk. Pixabay/Public domain Brandon Fornwalt, Tempus SVP of cardiology, called the findings “an important step toward shifting cardiac care from late-stage intervention to early risk detection,” stating the tool consistently spotted risk across varied clinical environments.
Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that brings artificial intelligence and machine learning to healthcare. It builds platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.